German Court Finds Medtronic Infringes Edwards' Transcatheter Valve Patent

German Court Finds Medtronic Infringes Edwards' Transcatheter Valve Patent 
IRVINE, CA -- (Marketwired) -- 07/12/13 --  Edwards Lifesciences
Corporation (NYSE: EW), the global leader in the science of heart
valves and hemodynamic monitoring, announced that the District Court
of Mannheim, Germany, today found that Medtronic infringes Edwards'
Spenser patent for transcatheter heart valve technology. The court
granted an injunction prohibiting the sale of CoreValve and CoreValve
Evolut systems in Germany, a recall of these products, and an
accounting for past damages.  
"We are very pleased with the court's ruling. Edwards will continue
to vigorously enforce our intellectual property to ensure continued
innovation in the treatment of patients with severe aortic stenosis,"
said Larry L. Wood, Edwards' corporate vice president, transcatheter
heart valves. 
Edwards filed this case in August 2012 and it relates to three
patents, including the Spenser patent EP 2 055 266 B1, which is in
effect until Oct. 2022. The Spenser patent is in place in other
European countries, including France, Italy, Spain, and others. 
The validity of the Spenser patent is separately being contested at
the European Patent Office. Today's decision is appealable, and it is
enforceable when Edwards provides the required bond to support the
injunction.  
About Edwards Lifesciences
 Edwards Lifesciences is the global leader
in the science of heart valves and hemodynamic monitoring. Driven by
a passion to help patients, the company partners with clinicians to
develop innovative technologies in the areas of structural heart
disease and critical care monitoring, enabling them to save and
enhance lives. Additional company information can be found at
www.edwards.com.  
This news release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E
of the Securities Exchange Act of 1934. These forward-looking
statements include, but are not limited to, statements regarding the
possibility for an injunction and recall of devices, and the timing
and potential results of future court decisions. Forward-looking
statements are based on estimates and assumptions made by management
of the company and are believed to be reasonable, though they are
i
nherently uncertain and difficult to predict. Our forward-looking
statements speak only as of the date on which they are made and we do
not undertake any obligation to update any forward-looking statement
to reflect events or circumstances after the date of the statement. 
Forward-looking statements involve risks and uncertainties that could
cause results to differ materially from those expressed or implied by
the forward-looking statements based on a number of factors,
including but not limited to, unexpected delays in, or outcomes of,
court proceedings in Mannheim and developments in the European Patent
Office. These factors are detailed in the company's filings with the
Securities and Exchange Commission including its Annual Report on
Form 10-K for the year ended December 31, 2012. 
Edwards, Edwards Lifesciences and the stylized E logo are trademarks
of Edwards Lifesciences Corporation. 
Media Contact:  
Sarah Huoh or Adrienne Turner
949-250-5070 
Investor Contact:  
David K. Erickson
949-250-6826